Home | Welcome to Contract Pharma   
Last Updated Monday, November 24 2014
Print RSS Feed

Search Results for 'Financial Report: AstraZeneca'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published November 21, 2014
Increased production capacity to support maturing biologics pipeline Read More »
By Kristin Brooks
Published January 3, 2014
Lead molecule and back-up compounds offer potential in cancer/inflammatory diseases Read More »
Published October 21, 2013
To explore compounds and targets with novel mechanisms with disease-modifying potential Read More »
Published September 11, 2013
Merck to receive $50 million upfront Read More »
By Gil Roth
Published October 17, 2012
Three-year pact covers safety assessment, development DMPK Read More »
Published March 14, 2012
To find compounds against respiratory and inflammatory targets Read More »
Published July 1, 2010
#5 - AstraZeneca 15 Stanhope Gate London W1K 1LN (UK) Tel: (44) 00 7304 5000 Fax: (44) 020 7304 5151 www.astrazeneca.com Headcount 63,000   Year Established 1999  … Read More »
Published April 23, 2007
AstraZeneca has entered into a definitive agreement to acquire MedImmune, Inc. for $15.6 billion in cash, approximately 11 times MedImmune's 2006 revenues. The acquisition adds to AZ's presence in the growing biological medicines and vaccines areas o… Read More »
Published February 1, 2007
AstraZeneca has entered into an agreement to acquire Arrow Therapeutics Ltd., a UK biotechnology company focused on the discovery and development of anti-viral therapies, for $150 million in cash. The transaction is expected to close early this year.… Read More »
By Kevin Lesnewski, Manager, Marketing & Business Intelligence
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On